Qi Xiao-wei, Zhang Fan, Wu Hong, Liu Jun-lan, Zong Bei-ge, Xu Chuan, Jiang Jun
1] Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China [2] Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.
Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Sci Rep. 2015 Mar 9;5:8924. doi: 10.1038/srep08924.
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in solid tumors remains inconclusive. Here, we report a systematic review and meta-analysis of the association between WT1 expression and prognosis in solid tumors. PubMed, Web of Science and Google Scholar were searched to identify studies exploring the impact of WT1 on clinical outcomes, including overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), relapse/recurrence-free survival (RFS) or progression-free survival (PFS), in solid cancer patients. Hazard ratio (HR) and 95% confidence interval (CI) were applied to assess the strength of these associations. Finally, a total of 29 eligible studies with 4090 patients were identified for qualitative analysis, and 22 studies with 3620 patients were enrolled for quantitative synthesis. Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21). Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35). In summary, our study suggests that WT1 may be a potential marker to predict DFS/RFS/PFS in solid tumor patients. Further studies are needed to confirm the role of WT1 expression in clinical practice.
尽管威尔姆斯瘤1（WT1）被认为是癌症免疫治疗中一个有前景的靶抗原，但WT1在实体瘤中的预后价值仍不明确。在此，我们报告一项关于WT1表达与实体瘤预后之间关联的系统评价和荟萃分析。检索了PubMed、科学网和谷歌学术，以确定探索WT1对实体癌患者临床结局影响的研究，这些临床结局包括总生存期（OS）、疾病特异性生存期（DSS）、无病生存期（DFS）、无复发/复发生存期（RFS）或无进展生存期（PFS）。应用风险比（HR）和95%置信区间（CI）来评估这些关联的强度。最后，共纳入29项符合条件的研究，涉及4090例患者进行定性分析，22项研究涉及3620例患者进行定量综合分析。总体而言，WT1的阳性表达与较差的OS（荟萃HR = 1.48，95%CI = 1.11 - 1.97）以及DFS/RFS/PFS（荟萃HR = 2.14，95%CI = 1.42 - 3.21）显著相关。亚组分析表明，WT1阳性表达可独立预测不良的DFS/RFS/PFS（荟萃HR = 1.86，95%CI = 1.04 - 3.35）。总之，我们的研究表明WT1可能是预测实体瘤患者DFS/RFS/PFS的一个潜在标志物。需要进一步研究来证实WT1表达在临床实践中的作用。
